We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Advertisement

Dynavax and GlaxoSmithKline Select Clinical Candidate in the Endosomal TLR Inhibitor Program

News   Feb 22, 2010

 
Dynavax and GlaxoSmithKline Select Clinical Candidate in the Endosomal TLR Inhibitor Program
 
 
Advertisement
 

RELATED ARTICLES

Trial of Saliva Test for COVID-19 Launched

News

Scientists from the Innovative Genomics Institute (IGI), the same UC Berkeley group that rapidly popped up a state-of-the-art COVID-19 testing laboratory in March, are now trialing a quicker way to obtain patient samples: through saliva.

READ MORE

SARS-CoV-2 Immunity Likely To Be Higher Than Antibody Testing Has Shown

News

A recent study suggests that many people who contract SARS-CoV-2 but have mild or no clinical signs still develop so-called T-cell-mediated immunity to the virus, even in the absence of a positive antibody test. The researchers conclude that this is likely to mean that public immunity is probably higher than antibody testing has so far suggested.

READ MORE

Novel Strategy Generates Useful Compounds for Drug Synthesis

News

A team of scientists has designed a novel catalytic method that can generate useful chiral compounds. This new strategy could provide an effective synthetic way to design pharmaceutical products.

READ MORE

 

Like what you just read? You can find similar content on the communities below.

Diagnostics

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE